Chondrocyte Death in Canine Osteochondral Explants Exposed To
Total Page:16
File Type:pdf, Size:1020Kb
Louisiana State University LSU Digital Commons LSU Master's Theses Graduate School 2009 Chondrocyte death in canine osteochondral explants exposed to 0.5 percent bupivacaine Geoffrey Stuart Hennig Louisiana State University and Agricultural and Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses Part of the Veterinary Medicine Commons Recommended Citation Hennig, Geoffrey Stuart, "Chondrocyte death in canine osteochondral explants exposed to 0.5 percent bupivacaine" (2009). LSU Master's Theses. 377. https://digitalcommons.lsu.edu/gradschool_theses/377 This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact [email protected]. CHONDROCYTE DEATH IN CANINE OSTEOCHONDRAL EXPLANTS EXPOSED TO 0.5 PERCENT BUPIVACAINE A Thesis Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Master of Science in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Veterinary Medical Sciences by Geoffrey Stuart Hennig B.A., Indiana University, 1995 D.V.M., Ross University, 2005 May 2009 ACKNOWLEDGMENTS This research could not have been completed without the support of many individuals. First of all, I have to thank my Masters committee: Dr. Giselle Hosgood, Dr. Loretta Bubenik, and Dr. Susanne Lauer. Their guidance over the years not only with this project, but also through the residency, is appreciated more than words can express. Dr. Hosgood deserves a special thank you for her expertise in experimental design and statistical analysis. I would also like to thank Dr. Timothy Morgan for his expertise and contributions to the project design and results in the area of histopathology. Many people contributed their time, ideas and expertise to the project and their contributions collectively enhanced the quality of this research. I would like to thank Kyle Waite who played an integral role in the logistics of this project. Also, Ms. Cheryl Crowder for her work with staining and histopathology preparations. Dr. Henk, Dr. Wu, and Greg McCormick in the microscopy lab provided their time, expertise and assistance with the laser confocal microscope. I also have to thank Ms. Samuella Frazier for all of her assistance in the laboratory. This project could not have been conducted without a grant provided by the Louisiana State University Veterinary Clinical Sciences Organized Research Fund. ii TABLE OF CONTENTS ACKNOWLEDGEMENTS……………………………………………………….. ii LIST OF TABLES…………………………………………………………………. v LIST OF FIGURES………………………………………………………………... vi ABSTRACT……………………………………………………………………….. vii CHAPTER 1: BACKGROUND AND REVIEW OF THE LITERATURE………. 1 1.1 Bupivacaine…………………………………………………………… 2 1.1.1 History of Local Anesthetics………………………………... 2 1.1.2 Properties of Local Anesthetics……………………………... 3 1.1.2.1 Chemistry of Local Anesthetics…………………... 3 1.1.2.2 Grouping of Local Anesthetics……………………. 3 1.1.2.3 Mechanism of Action ……………………………... 5 1.1.2.4 Differential Nerve Blockade………………………. 5 1.1.3 Pharmacokinetics of Local Anesthetics……………………... 6 1.1.3.1 Absorption………………………………………… 6 1.1.3.2 Distribution………………………………………... 6 1.1.3.3 Elimination………………………………………… 7 1.1.3.4 Toxicity……………………………………………. 8 1.1.4 Bupivacaine as an Intra-articular Analgesic………………… 9 1.1.4.1 Intra-articular Bupivacaine in People……………... 9 1.1.4.2 Intra-articular Bupivacaine in Dogs……………….. 10 1.2 Cartilage……………………………………………………………….. 10 1.2.1 Cartilage Cells……………………………………………….. 10 1.2.2 Cartilage Matrix……………………………………………... 11 1.2.3 Types of Cartilage…………………………………………… 11 1.2.4 Articular Cartilage Metabolism……………………………... 13 1.2.5 Response to Cartilage Injury……………………………….... 13 1.3 Arthroscopy Irrigating Solutions……………………………………… 14 1.4 Chondrocytotoxicity…………………………………………………... 16 1.5 Bupivacaine-Associated Chondrolysis………………………………... 19 CHAPTER 2: MATERIALS AND METHODS…………………………………... 25 2.1 Collection of Phase 1 Tissue Samples………………………………… 25 2.2 Treatment and Evaluation of Phase 1 Tissue Samples………………... 25 2.3 Collection of Phase 2 Tissue Samples………………………………… 26 2.4 Treatment and Evaluation of Phase 2 Tissue Samples ……………….. 26 2.5 Statistical Methods…………………………………………………….. 28 CHAPTER 3: RESULTS…………………………………………………………... 34 3.1 Phase 1 Results………………………………………………………... 34 3.2 Phase 2 Results………………………………………………………... 34 3.2.1 Surface Intact ……………………………………….. ……... 34 3.2.2 Surface Removed …………………………………… ……... 35 3.2.3 Surface Intact Compared to Surface Removed .…….............. 35 3.2.4 pH …………………………………………………… ……... 35 iii CHAPTER 4: DISCUSSION……………………………………………………… 46 CHAPTER 5: SUMMARY AND CONCLUSIONS………………………………. 53 REFERENCES…………………………………………………………………….. 56 APPENDIX I: PHASE 1 RAW METHYLENE BLUE PENETRATION DATA… 69 APPENDIX II: PHASE 2 RAW CHONDROCYTE DEATH DATA……………. 72 APPENDIX III: PHASE 2 RAW pH DATA ……………………………………... 91 VITA……………………………………………………………………………….. 98 iv LIST OF TABLES Table 2.1 Phase 1 osteochondral core treatments and sample size.……………….. 30 Table 2.2 Phase 2 osteochondral core treatments and sample size.……………….. 32 Table 3.1 Mean (standard deviation) methylene blue stain penetration measured in microns from the cut sides of the cores following either 15 or 30 minute exposure……………………………………………………………………………. 36 Table 3.2 Mean (standard deviation) proportional penetration of methylene blue stain from the articular surface of surface intact and surface removed osteochondral cores following either 15 or 30 minute exposure to canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP)………………………………………..... 37 Table 3.3 Mean (standard deviation) of chondrocyte death following 5 minute, 15 minute or 30 minute exposure to canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP) for surface intact (SI) and surface removed (SR) osteochondral cores………………………… 38 Table 3.4 Mean (standard deviation) pH of canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP) for surface intact (SI) and surface removed (SR) osteochondral cores before and after 5 minute treatment…………………………………………………………………. 41 Table 3.5 Mean (standard deviation) pH of canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP) for surface intact (SI) and surface removed (SR) osteochondral cores before and after 15 minute treatment………………………………………………………………... 42 Table 3.6 Mean (standard deviation) pH of canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP) for surface intact (SI) and surface removed (SR) osteochondral cores before and after 30 minute treatment………………………………………………………………... 43 v LIST OF FIGURES Figure 1.1 Molecular structure of bupivacaine……………………………………. 24 Figure 1.2 Basic molecular structure of local anesthetics………………………… 24 Figure 2.1 Photomicrograph at 10x of H&E stained osteochondral cores with an intact surface (A) and with the surface mechanically debrided (B)..………………. 29 Figure 2.2 Humeral heads (A) were cut in a grid-like fashion using a jigsaw (B) to harvest osteochondral cores with final dimensions of 6mm x 6mm x 6mm (C)... 29 Figure 2.3 Schematic diagram of the experimental design describing the tissue sample collection and treatment distribution for Phase 1………………………...... 30 Figure 2.4 Standard light microscopic digital image at 10x of a 1mm slice of a surface intact osteochondral core treated with 0.5% bupivacaine and methylene blue at 15 minutes (A) and 30 minutes (B)………………………………………… 31 Figure 2.5 Schematic diagram of the experimental design describing the tissue sample collection and treatment distribution for Phase 2………………………….. 32 Figure 2.6 Confocal microscopic digital image at 10x of a surface intact osteochondral core treated with canine chondrocyte culture media for 5 minutes stained with calcein AM (A) and ethidium homodimer-1 (B). Images A and B are superimposed in image C showing the greater chondrocyte death that occurred in the superficial zone………………………………………………………………… 33 Figure 3.1 Mean (standard deviation) proportional penetration of methylene blue stain from the articular surface of surface intact and surface removed osteochondral cores following either 15 or 30 minute exposure to canine chondrocyte culture medium (CCCM), 0.5% bupivacaine (B), or 0.5% bupivacaine with preservative (BP)………………………………………...... 37 Figure 3.2 Mean % chondrocyte death comparisons within treatment solutions across time in the superficial zone of surface intact osteochondral cores…………. 39 Figure 3.3 Mean % chondrocyte death comparisons across time in the superficial zone of surface intact osteochondral cores………………………………………… 39 Figure 3.4 Mean % chondrocyte death comparisons within treatment solutions across time in the superficial zone of surface removed osteochondral cores ……... 40 Figure 3.5 Mean % chondrocyte death comparisons across time in the superficial zone of surface removed osteochondral cores……………………………………... 40 Figure 3.6 Mean pH within treatment solutions across time of surface intact cores………………………………………………………………………………... 44 Figure 3.7 Mean pH across time of surface intact cores…………………………... 44 Figure 3.8 Mean pH within treatment solutions across time of surface removed cores………………………………………………………………………………..